GERMANTOWN, Maryland and HILDEN, Germany, January 18, 2018 /PRNewswire/ --
Click here for the full press release.
Investor Relations John Gilardi e-mail: ir@QIAGEN.com +49-2103-29-11711
Public Relations Dr. Thomas Theuringer e-mail: pr@QIAGEN.com +49-2103-29-11826
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All